
Aravive ARAV
Quarterly report 2023-Q3
added 11-09-2023
Aravive General and Administrative Expenses 2011-2026 | ARAV
General and Administrative Expenses — these are a part of a company's operating expenses that are not directly related to the production of goods or the provision of services but are necessary for the overall functioning of the business.What these expenses include
- Salaries of administrative staff (executives, HR, accountants, legal personnel)
- Office rent and utilities
- Office equipment and IT infrastructure
- Professional services (auditors, lawyers, consultants)
- Insurance
- General administrative travel and representation expenses
- Cost control
A high level of such expenses may indicate inefficient management or an overly complex structure - Profitability
Reducing administrative expenses while maintaining stable revenue increases operating profit - Comparative analysis
Investors can compare this metric as a percentage of revenue among companies in the same industry - Business flexibility
Companies with a flexible and controlled expense structure are more resilient to revenue declines
Annual General and Administrative Expenses Aravive
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 13 M | 10.6 M | 13.1 M | 13.7 M | 27.4 M | 29.9 M | 24.3 M | 22.5 M | 13.5 M | 4.43 M | 1.94 M | 1.78 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 29.9 M | 1.78 M | 14.7 M |
Quarterly General and Administrative Expenses Aravive
| 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2.94 M | 3.07 M | 3.49 M | - | 2.84 M | 3.73 M | 3.09 M | - | 2.64 M | 3.08 M | 2.38 M | - | 2.72 M | 3.2 M | 3.95 M | - | 3.16 M | 3.29 M | 4.59 M | - | 5.19 M | 6 M | 4.92 M | 7.57 M | 7.07 M | 7.57 M | 7.66 M | 5.76 M | 6.75 M | 5.91 M | 5.92 M | 4.62 M | 5.12 M | 7.56 M | 5.18 M | 4.34 M | 3.58 M | 2.88 M | 2.71 M | 2.4 M | 685 K | 656 K | 682 K | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 7.66 M | 656 K | 4.18 M |
General and Administrative Expenses of other stocks in the Biotechnology industry
| Issuer | General and Administrative Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
78.3 M | - | 2.43 % | $ 254 M | ||
|
Aligos Therapeutics
ALGS
|
20.7 M | $ 8.74 | 0.23 % | $ 86.4 M | ||
|
Allakos
ALLK
|
45.1 M | - | - | $ 28.6 M | ||
|
Alterity Therapeutics Limited
ATHE
|
5.51 M | $ 3.62 | -1.09 % | $ 8.71 B | ||
|
Aptinyx
APTX
|
19.8 M | - | -39.0 % | $ 4.57 M | ||
|
BioNTech SE
BNTX
|
286 M | $ 98.41 | 1.77 % | $ 27.2 B | ||
|
Burford Capital Limited
BUR
|
99.3 M | $ 4.71 | 4.9 % | $ 760 M | ||
|
Cabaletta Bio
CABA
|
29.6 M | $ 3.26 | 1.87 % | $ 328 M | ||
|
I-Mab
IMAB
|
900 M | - | - | $ 866 M | ||
|
AlloVir
ALVR
|
11 M | - | 4.14 % | $ 49.1 M | ||
|
Applied Molecular Transport
AMTI
|
37.4 M | - | - | $ 10.1 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
1.4 B | - | - | $ 40.3 B | ||
|
Genfit SA
GNFT
|
16.2 M | - | 2.54 % | $ 160 B | ||
|
Biophytis SA
BPTS
|
7.15 M | - | -13.47 % | $ 169 M | ||
|
Brainstorm Cell Therapeutics
BCLI
|
5.78 M | - | -2.5 % | $ 5.88 M | ||
|
Applied Therapeutics
APLT
|
20.6 M | - | - | $ 8.42 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
4.66 M | - | -1.52 % | $ 24.7 M | ||
|
BeiGene, Ltd.
BGNE
|
2.08 B | - | 0.49 % | $ 251 B | ||
|
bluebird bio
BLUE
|
166 M | - | - | $ 546 M | ||
|
Midatech Pharma plc
MTP
|
4.95 M | - | -18.52 % | $ 27.3 M | ||
|
Amphastar Pharmaceuticals
AMPH
|
85.9 M | $ 21.38 | 0.09 % | $ 999 M | ||
|
Checkpoint Therapeutics
CKPT
|
20.1 M | - | - | $ 169 M | ||
|
Институт стволовых клеток человека
ISKJ
|
25.8 M | - | - | - | ||
|
Adverum Biotechnologies
ADVM
|
63.1 M | - | - | $ 86.2 M | ||
|
Advaxis
ADXS
|
12.2 M | - | -9.65 % | $ 45.9 M | ||
|
Clearside Biomedical
CLSD
|
11.9 M | - | - | $ 25.3 M | ||
|
Aeterna Zentaris
AEZS
|
5.92 M | - | 5.93 % | $ 314 M | ||
|
AgeX Therapeutics
AGE
|
11 M | - | -10.17 % | $ 12.2 K | ||
|
Aeglea BioTherapeutics
AGLE
|
47.9 M | - | - | $ 1.01 B | ||
|
Akebia Therapeutics
AKBA
|
107 M | $ 1.56 | 6.12 % | $ 401 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
17 M | - | - | $ 26.5 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
3.66 M | $ 3.05 | 4.45 % | $ 5.02 M | ||
|
Aquestive Therapeutics
AQST
|
79.8 M | $ 4.15 | -0.95 % | $ 444 M | ||
|
Arcutis Biotherapeutics
ARQT
|
275 M | $ 25.09 | 4.02 % | $ 3.19 B | ||
|
Chimerix
CMRX
|
24.6 M | - | - | $ 756 M | ||
|
Concert Pharmaceuticals
CNCE
|
22.5 M | - | - | $ 401 M | ||
|
AIkido Pharma
AIKI
|
23.8 M | - | 1.93 % | $ 17.4 M | ||
|
Celldex Therapeutics
CLDX
|
43.8 M | $ 33.33 | 2.27 % | $ 2.21 B | ||
|
Autolus Therapeutics plc
AUTL
|
132 M | $ 1.48 | 0.68 % | $ 394 M | ||
|
Aptose Biosciences
APTO
|
13.4 M | - | -45.71 % | $ 1.2 M | ||
|
Cidara Therapeutics
CDTX
|
20.6 M | - | - | $ 1.41 B | ||
|
Evogene Ltd.
EVGN
|
7.25 M | $ 0.82 | 0.02 % | $ 27.9 M | ||
|
AVROBIO
AVRO
|
24 M | - | 1083.1 % | $ 745 M | ||
|
Forte Biosciences
FBRX
|
12.4 M | $ 32.42 | 5.95 % | $ 420 M | ||
|
CNS Pharmaceuticals
CNSP
|
6.21 M | $ 2.64 | 8.42 % | $ 1.17 M | ||
|
Ayala Pharmaceuticals
AYLA
|
1.53 M | - | - | $ 7.46 M | ||
|
AstraZeneca PLC
AZN
|
15.2 B | - | - | $ 96.9 B | ||
|
Akero Therapeutics
AKRO
|
37.9 M | - | - | $ 3.67 B | ||
|
CTI BioPharma Corp.
CTIC
|
84.8 M | - | - | $ 1.2 B |